Back to top

Image: Bigstock

Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4

Read MoreHide Full Article
Ecolab Inc. ECL reported fourth-quarter 2019 adjusted earnings per share of $1.66, missing the Zacks Consensus Estimate of $1.68. Nonetheless, adjusted EPS rose 7.8% on a year-over-year basis.
 
This Zacks Rank #3 (Hold) company’s quarterly net sales amounted to $3.82 billion, up 1.7% from the year-ago figure. However, net sales lagged the Zacks Consensus Estimate of $3.87 billion.
 
2019 at a Glance
 
Ecolab’s 2019 revenues were $14.91 billion, missing the Zacks Consensus Estimate of $14.98 billion but increasing 1.6% from the prior-year quarter.
 
Adjusted EPS was $5.93, beating the Zacks Consensus Estimate of $5.86 and rising 13% from the year-ago quarter.
 
Segmental Analysis
 
Global Industrial
 
Sales at the segment grew 5.5% year over year to $1.47 billion, driven by solid growth in Water, Food & Beverage, and Life Sciences units. Geographically, all regions recorded impressive sales growth in the quarter.
 
Global Institutional
 
Sales improved 3.3% year over year to $1.34 billion, led by robust growth in the Specialty business. Sales at the segment significantly grew across all geographies.

Ecolab Inc. Price, Consensus and EPS Surprise

Ecolab Inc. Price, Consensus and EPS Surprise

Ecolab Inc. price-consensus-eps-surprise-chart | Ecolab Inc. Quote

Global Energy
 
Sales at the segment dropped 3% year over year to $845.4 million. Per management, upstream sales dropped slightly owing to a decline in the well-stimulation business.
 
Other
 
Sales rose 3.8% year over year to $227.4 million, reflecting strong gains in both Pest Elimination and Colloidal Technologies across all geographies.
 
Margin Analysis
 
Ecolab registered adjusted gross profit of $1.62 billion, up 4.6% year over year. As a percentage of revenues, adjusted gross margin in the fourth quarter was 42.4%, up 120 basis points (bps).
 
Adjusted operating income in the quarter was $645.6 million, up 6.9% year over year. Adjusted operating margin in the quarter was 16.9%, which expanded 80 bps year over year.
 
Guidance
 
For 2020, Ecolab expects adjusted EPS within $6.33-$6.53, calling for 9-12% growth from 2019. The Zacks Consensus Estimate for the same stands at $6.45 per share.
 
Adjusted gross margin is expected to be 42-43% of net sales.
 
For first-quarter 2020, Ecolab expects adjusted EPS within $1.05-$1.13, mirroring year-over-year growth of 6-13%. The corresponding Zacks Consensus Estimate is pegged at $1.17 per share.
 
The coronavirus outbreak is expected to have a 5-cent unfavorable impact on adjusted EPS.
 
Adjusted gross margin is expected to be 41-42% of quarterly sales.
 
Earnings of Other MedTech Majors at a Glance
 
Some better-ranked stocks — which reported solid results this earnings season — include Stryker Corporation SYK, Accuray Incorporated ARAY and IDEXX Laboratories, Inc. (IDXX - Free Report) . You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
 
Stryker reported fourth-quarter 2019 adjusted EPS of $2.49, outpacing the Zacks Consensus Estimate by 1.2%. Fourth-quarter reported revenues of $4.13 billion surpassed the Zacks Consensus Estimate by 0.7%. The company carries a Zacks Rank #2 (Buy).
 
Accuray reported second-quarter fiscal 2020 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss of 7 cents. Net revenues of $98.8 million outpaced the Zacks Consensus Estimate by 0.3%. The company sports a Zacks Rank #1.
 
IDEXX Laboratories reported fourth-quarter 2019 adjusted EPS of $1.04, which beat the Zacks Consensus Estimate of 91 cents by 14.3%. Revenues were $605.4 million, surpassing the Zacks Consensus Estimate by 0.9%. The company carries a Zacks Rank of 2.
 
Today's Best Stocks from Zacks
 
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
 
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

In-Depth Zacks Research for the Tickers Above


Choose a ticker to receive a FREE report - normally $25 each:


IDEXX Laboratories, Inc. (IDXX) - free report >>